 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- | begacestat (GSI-953) / Pfizer
Preclinical, Journal: Mesenchymal Stem Cells and Begacestat Mitigate Amyloid-? 25-35-Induced Cognitive Decline in Rat Dams and Hippocampal Deteriorations in Offspring. (Pubmed Central) - Jul 29, 2023
Finally, the treatments with BM-MSC or GSI-953 are globally beneficial against A? 25-35-induced brain alterations, particularly by suppressing neural inflammation, inhibiting microglial cell activation, restoring developmental plasticity, and increasing neurotrophic signaling.
- | donepezil / Generic mfg.
Preclinical, Journal: Computational and in-vitro validation of natural molecules as potential Acetylcholinesterase inhibitors and neuroprotective agents. (Pubmed Central) - Apr 16, 2020
25-35-induced brain alterations, particularly by suppressing neural inflammation, inhibiting microglial cell activation, restoring developmental plasticity, and increasing neurotrophic signaling. Quercetin and caffeine have the potential as "disease-modifying drugs" and may find application in the management of neurological disorders such as AD.